FAYETTEVILLE, Ark., Feb. 9, 2026 /PRNewswire/ -- HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused healthcare accelerator that facilitates guaranteed ...

Semaglutide reduced major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease regardless of baseline adiposity. Cardiovascular benefit was largely ...

Systemic inflammation has been elevated to a modifiable cardiovascular risk factor requiring assessment, monitoring, and modification, based on consensus recommendations.

Clean air laws have led to a significant reduction in long-term exposure to fine particulate air pollution across much of the ...

Cardiovascular disease remains the number one killer of women, yet awareness among younger generations, including Gen Z and ...

Risk prediction has been used in the primary prevention of cardiovascular disease for >3 decades. Contemporary cardiovascular risk assessment relies on multivariable models, which integrate ...

Guidelines emphasize single-pill combinations and deprescribing strategies to combat polypharmacy and hyperpolypharmacy in ...

AMA member Evan Jacobs, MD, of CenterWell Senior Primary Care, says the specialty can be highly demanding, and not just because of patients’ needs.

Semaglutide, the active ingredient in the weight-loss medications Ozempic and Wegovy, offers substantial cardiovascular ...

New research indicates that men develop cardiovascular disease seven years earlier than women, suggesting that men may ...

Men's heart health tends to decline earlier in life, and the difference is driven largely by coronary heart disease, which ...

Higher rates of death among younger Australians from cardiovascular disease has been linked to being overweight or obese, a ...